LCN2 and glioblastoma: Ultimately, an IPA network analysis based on altered gene expression signatures in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham reveals TSPO as a mediator for elevated expression of genes associated with poor prognosis [e.g., CCL2 (53)], therapy resistance [e.g., CD74 (54), LCN2 (55)] and immunosuppression [e.g., CHIL1/CHI3L1 (51); Fig. 5D], highlighting its potential for in vivo characterization of the immune phenotype in brain of patients with glioblastoma.